Argenx Se (ARGX) EBT (2016 - 2026)
Argenx Se (ARGX) posted EBT of $438.0 million for Q1 2026, up 8.61% on a QoQ basis from $403.3 million in Q4 2025, and up 116.44% year-over-year from $202.4 million in Q1 2025.
Argenx Se (ARGX) EBT (2016 - 2026) Analysis & Trends
Argenx Se's EBT history runs 11 years deep, the most recent figure standing at $438.0 million for Q1 2026.
- Quarterly EBT rose 116.44% year-over-year to $438.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 321.52% YoY) and the FY2025 annual result came in at $1.3 billion, up 1401.06% from the prior year.
- EBT was $438.0 million for Q1 2026 at Argenx Se, up from $403.3 million in the prior quarter.
- Across five years, EBT topped out at $438.0 million in Q1 2026 and bottomed at -$677.1 million in Q2 2022.
- A 5-year average of $104.2 million and a median of $83.9 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT plunged 743.33% — and 2025, when it soared 2012.28%.
- Argenx Se's EBT stood at $41.2 million in 2022, then soared by 48.35% to $61.2 million in 2023, then soared by 37.06% to $83.9 million in 2024, then surged by 380.97% to $403.3 million in 2025, then climbed by 8.61% to $438.0 million in 2026.
- Business Quant data shows ARGX's EBT at $438.0 million in Q1 2026, $403.3 million in Q4 2025, and $386.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 221.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 438.00 Mn |
| Dec 31, 2025 | 403.29 Mn |
| Sep 30, 2025 | 386.05 Mn |
| Jun 30, 2025 | 286.90 Mn |
| Mar 31, 2025 | 202.36 Mn |
| Dec 31, 2024 | 83.85 Mn |
| Sep 30, 2024 | 88.02 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Mar 31, 2024 | -74.35 Mn |
| Dec 31, 2023 | 61.18 Mn |
| Sep 30, 2023 | 83.28 Mn |
| Jun 30, 2023 | -83.86 Mn |
| Mar 31, 2023 | 76.18 Mn |
| Dec 31, 2022 | 41.24 Mn |
| Sep 30, 2022 | 241.02 Mn |
| Jun 30, 2022 | -677.12 Mn |
| Mar 31, 2022 | 230.07 Mn |
| Dec 31, 2021 | -244.88 Mn |
| Sep 30, 2021 | 230.87 Mn |
| Jun 30, 2021 | 105.25 Mn |